

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

PROVECTUS PHARMACEUTICALS INC
Form 8-K
June 29, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 29, 2004

PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	0-9410	90-0031917
----- (State or Other Jurisdiction of Incorporation or Organization)	----- (Commission File Number)	----- (I.R.S. Employer Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee		37931
----- (Address of Principal Executive Offices)		----- (Zip Code)
Registrant's telephone number, including area code:	865/769-4011	-----

(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On June 29, 2004, Provectus Pharmaceuticals, Inc. (the "Company") announced that it completed a fixed price financing of \$1 million for the purchase of restricted common shares.

The Company issued a press release which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

99.1 Press release dated June 29, 2004.

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Provectus Pharmaceuticals, Inc.

Dated: June 29, 2004

By: /s/ H. Craig Dees

H. Craig Dees
Chief Executive Officer

Exhibit Index

Exhibit No. -----	Description -----
99.1	Press Release of Provectus Pharmaceuticals, Inc.